Antithrombotic medicines; Belgium; Drug-related problems; Pharmaceutical care; Pharmacy practice
Abstract :
[en] Background Community pharmacists have an important task in the follow-up of patients treated with antithrombotics. When delivering these medicines, pharmacists can encounter drug–related problems (DRPs) with substantial clinical and economic impact. Objective To investigate the amount and type of antithrombotic related DRPs as well as how community pharmacists handled these DRPs. Setting Belgian community pharmacies. Methods MSc pharmacy students of six Belgian universities collected data about all DRPs encountered by a pharmacist during ten half days of their pharmacy internship. Data were registered about DRPs detected at delivery and in an a posteriori setting, when consulting the medical history of the patient. Classification of the DRP, cause of the DRP, intervention and result of the intervention were registered. Main outcome measure Amount and type of antotrombitocs related DRPs occurring in community pharmacies, as well as how community pharmacists handled these DRPs. Results 3.1 % of the 15,952 registered DRPs concerned antithrombotics. 79.3 % of these DRPs were detected at delivery and 20.7 % were detected a posteriori. Most antithrombotic-related DRPs concerned problems with the choice of the drug (mainly because of drug–drug interactions) or concerned logistic problems. Almost 80 % of the antithrombotic-related DRPs were followed by an intervention of the pharmacist, mainly at the patient’s level, resulting in 90.1 % of these DRPs partially or totally solved. Conclusion Different DRPs with antithrombotic medication occurred in Belgian community pharmacies. About 20 % was detected in an a posteriori setting, showing the benefit of medication review. Many of the encountered DRPs were of technical nature (60.7 %). These DRPs were time-consuming for the pharmacist to resolve and should be prevented. Most of the DRPs could be solved, demonstrating the added value of the community pharmacist as first line healthcare provider.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Desmaele, Sara
De Wulf, Isabelle
Dupont, Alain G.
Putman, K
Puttemans, F
Boussery, K
De Meyer, GRY
De Vriese, C
Foulon, V
Lacour, V
Van Hees, Thierry ; Université de Liège > Département de pharmacie > Pharmacie clinique et pharmacie hospitalière
Steurbaut, Stéphane
Language :
English
Title :
Pharmacists' role in handling problems with prescriptions for atithrombotic medication in Belgian community pharmacies
Publication date :
August 2015
Journal title :
International Journal of Clinical Pharmacy
ISSN :
2210-7703
eISSN :
2210-7711
Publisher :
Springer
Volume :
37
Issue :
4
Pages :
656-668
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
K. Putman, F. Puttemans, K. Boussery, G.R.Y. De Meyer, C. De Vriese, V. Foulon, V. Lacour and T. Van Hees have contributed to the redaction of the article as members of the DRP-studygroup
Silva MV, Dusse LM, Vieira LM, Carvalho M. Platelet antiaggregants in primary and secondary prevention of atherothrombotic events. Arq Bras Cardiol. 2013;100(6):e78–84.
Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: a review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013;1(2):83–97.
Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285–91.
Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988–1996. Med J Aust. 1998;168(8):405–8.
Walsh D, Lavan A, Cushen AM, Williams D. Adverse drug reactions as a cause of admission to a Dublin-based university teaching hospital. Ir J Med Sci. 2014.
Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489–97.
Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):546S–92S.
Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010;74(11):2479–500.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.
Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):74–90.
Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e326S–50S.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. Ocused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.
PCNE. Classification for drug related problems V6.2. [Internet] Zuidlaren, NL: Pharmaceutical care network Europe foundation; 2010 [cited 2015 2015-02-02]; Available from: http://www.pcne.org/upload/files/11_PCNE_classification_V6-2.pdf.
Westerlund T, Gelin U, Pettersson E, Skarlund F, Wagstrom K, Ringbom C. A retrospective analysis of drug-related problems documented in a national database. Int J Clin Pharm. 2013;35(2):202–9.
Westerlund T, Marklund B. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. J Clin Pharm Ther. 2009;34(3):319–27.
Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists’ modifications of prescription errors. Br J Clin Pharmacol. 2004;58(5):503–11.
De Vriese C, Sansterre G, De Wulf I, Claeys C. Adaptation and validation of a drug related problem classification tool in community pharmacy. Int J Clin Pharm. 2013;35(3):497–8.
van Noord E, van der Graaf C, de Gier J. Onderzoek naar prescriptie-interventies in een openbare apotheek. PW Wetenschappelijk Platform. 2009;3(6):6.
WHO. ATC/DDD Index. [Internet] Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2014 [updated 2013-12-19; cited 2014 2014-03-10]; Available from: http://www.whocc.no/.
